[go: up one dir, main page]

EP0950044A1 - Preparation de gabapentine - Google Patents

Preparation de gabapentine

Info

Publication number
EP0950044A1
EP0950044A1 EP97954134A EP97954134A EP0950044A1 EP 0950044 A1 EP0950044 A1 EP 0950044A1 EP 97954134 A EP97954134 A EP 97954134A EP 97954134 A EP97954134 A EP 97954134A EP 0950044 A1 EP0950044 A1 EP 0950044A1
Authority
EP
European Patent Office
Prior art keywords
gabapentin
solvent
butanol
hydrochloride
methanol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97954134A
Other languages
German (de)
English (en)
Other versions
EP0950044A4 (fr
Inventor
Michael Pesachovich
Claude Singer
Gideon Pilarski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of EP0950044A1 publication Critical patent/EP0950044A1/fr
Publication of EP0950044A4 publication Critical patent/EP0950044A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/38—Separation; Purification; Stabilisation; Use of additives
    • C07C227/40—Separation; Purification
    • C07C227/42—Crystallisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/28—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Definitions

  • This invention relates to a new process for converting gabapentin hydrochloride salt to gabapentin via a novel polymorphic form of gabapentin.
  • Gabapentin is 1- (aminomethyl) -1-cyclohexaneacetic acid, having the chemical structure:
  • Gabapentin is used in the treatment of cerebral diseases such as epilepsy.
  • the literature describes many ways of preparing gabapentin from a variety of starting materials.
  • U.S. Patent 4,024,175 describes at least three methods of preparing gabapentin from cyclohexyl-1, 1-diacetic acid. Each of these methods results in the formation of gabapentin hydrochloride salt, which may be converted to 1- (aminomethyl) -1- cyclohexaneacetic acid by treatment with a basic ion exchanger and then crystallized from a solvent such as ethanol/ether .
  • U.S. Patent 4,894,476 specifically discloses an improved method for converting the hydrochloride salt into the free amino acid. This involves pouring a deionized water solution of the salt over an ion exchange column, eluting with deionized water, producing a slurry from the eluate, adding an alcohol to the slurry, centrifuging and drying the slurry to obtain the free amino acid.
  • gabapentin is crystalline and exhibits an X-ray diffraction pattern with peaks of 2-theta values at 7.8, 13.3, 15.0, 17.0, 20.4, 21.3, 23.1, 23.6, 25.7, 27.0 and 28.2 degrees.
  • polymorph form "II" the commercially available polymorphic form of gabapentin is referred to as polymorph form "II".
  • the present invention relates to an improved method for purifying gabapentin comprising converting gabapentin hydrochloride salt to gabapentin form II.
  • the present invention avoids the disadvantages associated with prior art methods, by adding alternative steps and by proceeding via a novel polymorphic form of gabapentin.
  • the present invention relates to a method of converting gabapentin hydrochloride salt to gabapentin form II, comprising reacting a solution of gabapentin hydrochloride with an additional amine in a first solvent to produce a novel polymorphic form as a precipitate, thereafter, converting the novel polymorphic form to form II by forming a suspension and/or a solution of the precipitate in methanol, and then recovering gabapentin form II.
  • the present invention further relates to a novel polymorphic form of gabapentin designated as gabapentin form III.
  • the polymorph may be identified by its unique X-ray diffraction pattern.
  • a further aspect of the present invention relates to the novel polymorphic form of gabapentin that is of use as an intermediate in the preparation of polymorphic form II.
  • Fig. 1 is an x-ray diffraction pattern of a sample of gabapentin hydrate.
  • Fig. 2 is an x-ray diffraction pattern of gabapentin form II.
  • Figs. 3a and 3b are x-ray diffraction pattern of gabapentin form III, possibly containing small amounts of gabapentin form II and/or gabapentin hydrate.
  • Fig. 4 is an FTIR (Fourier Transform Infra Red) spectrum of gabapentin hydrate.
  • Fig. 5 is an FTIR spectrum of gabapentin form II.
  • Fig. 6 is an FTIR spectrum of gabapentin form III, possibly containing small amounts of gabapentin form II and/or gabapentin hydrate.
  • the method of the present invention comprises:
  • the gabapentin hydrochloride used as a starting material in the process of the present invention is substantially free of other inorganic salts such as sodium chloride and sodium bromide, that is, such impurities are only present in trace amounts.
  • gabapentin hydrochloride containing inorganic salts may be used subject to the addition of a further step for removing the inorganic salts prior to mixing gabapentin hydrochloride with the additional amine.
  • gabapentin hydrochloride containing inorganic salts may optionally be pre-treated to remove the inorganic salts by the steps of (a) dissolution in a solvent in which gabapentin hydrochloride is soluble, but the inorganic salts are not; (b) filtration of the inorganic salts and, optionally, (c) evaporating the solvent to recover gabapentin hydrochloride substantially free of inorganic salts.
  • Appropriate solvents for the optional pre-treatment step include those selected from the group consisting of methanol, ethanol, n-propanol, isopropanol, butanol, t-butanol, n-butanol, ethyleneglycolmonomethylether, benzylalcohol or dimethylacetamide.
  • the pre-treatment solvent is identical to the first solvent.
  • This pre-treatment solvent which is identified in Table 1 and in the claims as the "second solvent”, would be used prior to using the "first solvent", if, in fact, this optional pre-treament step is included in the process.
  • the second step of the present invention comprises mixing a solution of the gabapentin hydrochloride in a solvent that contains an additional amine.
  • the solvent may be any solvent in which the hydrochloride salt of the additional amine is soluble but in which gabapentin form III is insoluble, such that a precipitate of gabapentin form III is formed.
  • Such solvents are preferably selected from the group consisting of ethyl acetate, dimethylcarbonate, ethanol, butanol, t-butanol, n-butanol, methanol, acetonitrile, toluene, isopropylacetate, isopropanol, methylethylketone, acetone, ethyleneglycolmonomethylether, methylene chloride, chloroform, benzylalcohol or dimethylacetamide.
  • the precipitated gabapentin which may be separated by filtration, is characterized herein as a novel polymorphic form of gabapentin, possessing a crystalline structure characterized by peaks in the powder X ray diffraction pattern with 2-theta values at 6.11, 12.22, 17.00, 18.20, 19.94, 20.81, 24.54, and 25.11 degrees, all ⁇ 0.2 degrees.
  • the x-ray diffraction pattern in the samples obtained appears to show a preferred orientation in which the peak at 6.11 degrees is larger than any other peak in the pattern, and the peaks at 12.22 and 24.54 degrees are larger than any of the remaining peaks in the pattern.
  • This polymorph is referred to herein as gabapentin form III.
  • Slurrying may be performed by suspending the precipitated gabapentin in methanol by mixing, stirring, and/or providing continuous agitation with some mechanical device so as to induce transformation into the gabapentin form II that is the commercially available polymorphic form of gabapentin. Gabapentin form II may then be filtered off and washed.
  • the precipitated gabapentin may be crystallized from methanol with heating by reflux until dissolved, cooling, optionally seeding with gabapentin, followed by further cooling, and then collecting and drying the crystals of gabapentin form II. Second and multiple crops may be obtained from the concentrated mother liqueurs.
  • Suitable amines for use in the present invention include triethylamine, tributylamine, tripropylamine, trihexylamine, diethylamine, ethanolamine and benzylamine.
  • the amine is tributylamine.
  • the form II gabapentin obtained by the methods of the present invention may be crystallized using processes known in the art.
  • Gabapentin hydrochloride containing inorganic salts NaCl, NaBr
  • inorganic salts NaCl, NaBr
  • Example 4 Variant A was dissolved in 150 ml isopropanol and mixed at 25°C. Active carbon (0.9 g) was added and the suspension mixed for a further 2 hours. The inorganic salts were removed by filtering. The filter cake was washed twice with 15 ml isopropanol and the washings were added to the gabapentin hydrochloride solution.
  • the still humid filter cake from step 2 was suspended in 210 ml of methanol and the suspension was heated to reflux (65°C) . If dissolution was incomplete, additional methanol was added.
  • the reactor content was cooled to 34°C at which temperature crystallization was induced by seeding with pure Form II gabapentin base (0.1 g) .
  • the reactor content was cooled to 25°C and methanol was distilled by vacuum distillation. Approximately 160 ml of methanol was collected. Then the suspension was cooled to 0-10°C and maintained at this temperature for 2 hours .
  • the crystalline gabapentin was separated by filtration from the suspension.
  • the filter cake was washed with 20 ml methanol and then dried under vacuum at 35°C. 10.8 g of crystalline gabapentin form II (yield 72%) was thus obtained.
  • Example 2-20 The method of Example 1 was followed using the slurrying technique of step C(l) and employing the amines and solvents shown in Table 1 below. The percent yields are of purified product except where marked with an asterisk (*) , where the yield was measured at the stage prior to the slurrying in methanol. Table 1. Summary of the first solvent, second solvent, amine and yield of examples 2-20.
  • IPA isopropanol MEK methyl ethyl ketone ACN acetonitrile EGMME ethyleneglycol monomethylether BzOH benzyl alcohol TBA tributylamine MeOH methanol BzA benzylamine CH 2 C1 2 methylene chloride IPA Ac isopropylacetate THA trihexylamine DMC dimethylcarbonate TPA tripropylamine (t)-BuOH (tert) -butanol Et Ac ethyl acetate TEA triethylamine DMA dimethylacetamide DEA diethylamine
  • the gabapentin form III was characterized by comparing the x- ray diffraction pattern and the FTIR absorption spectra of gabapentin form III with gabapentin form II and gabapentin hydrate.
  • the x-ray powder diffraction patterns of Figures 1, 2, and 3a were obtained using a Philips x-ray powder diffractometer with the following parameters:
  • Type of radiation copper K .
  • Figure 3b was obtained using a Siemens B5100 with a presample (K ⁇ ! only) monochromator, step scan, Cu radiation, beam slits 0.3, receiving slit 0.05, standard Siemens rotating sample holder, start/stop/step angles in degrees were 4.0, 35, and 0.04, with a step duration of 15 seconds.
  • Standard Siemens D- 5000 software was used.
  • the diffractometer was calibrated with NIST large d-spacing standard. No theta-compensating slits were employed.
  • Figs. 1-3 The x-ray spectra of gabapentin hydrate, gabapentin form II and gabapentin form III are shown in Figs. 1-3, respectively.
  • the main diffraction peaks that characterize each material are listed in Table 2.
  • FTIR spectra for gabapentin hydrate, gabapentin form II and gabapentin form III are shown in Figs. 4-6, respectively.
  • the FTIR peaks are summarized in Table 3,
  • the hydrate form typically exists as large crystals with undefined shapes.
  • Form II typically exists as plate shaped crystals.
  • Form III typically exists as small rhomboidal crystals.
  • the melting point for gabapentin was not determined since gabapentin decomposes prior to melting.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

L'invention concerne un procédé permettant de convertir du chlorhydrate de gabapentine essentiellement exempt de sels inorganiques en gabapentine de forme (II). Ce procédé comprend les étapes consistant; 1) à obtenir du chlorhydrate de gabapentine essentiellement exempt de sels inorganiques; 2) à mélanger une solution dudit chlorhydrate de gabapentine avec un amine supplémentaire dans un premier solvant, afin d'obtenir un précipité renfermant de la gabapentine; puis 3) à récupérer la gabapentine de forme II à partir dudit précipité. La gabapentine précipitée constitue une nouvelle forme polymorphe de gabapentine, qui possède une structure cristalline caractérisée par de nouvelles crêtes dans le diagramme de diffraction des rayons X de la poudre et dans le spectre infrarouge à transformée de Fourier. Cette nouvelle forme de gabapentine est ici désignée par la gabapentine de forme III. L'étape de récupération peut par exemple comprendre un ou deux autres procédés, qui consistent à mettre en suspension la gabapentine de forme II dans du méthanol, puis à filtrer cette suspension pour obtenir de la gabapentine de forme II, ou à rendre la gabapentine de forme III soluble dans le méthanol en la faisant bouillir à reflux avant de la faire refroidir pour obtenir la gabapentine de forme II par cristallisation.
EP97954134A 1996-12-24 1997-12-24 Preparation de gabapentine Withdrawn EP0950044A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL11989096 1996-12-24
IL11989096A IL119890A (en) 1996-12-24 1996-12-24 Gabapentin form iii and preparation of gabapentin form ii
PCT/US1997/023164 WO1998028255A1 (fr) 1996-12-24 1997-12-24 Preparation de gabapentine

Publications (2)

Publication Number Publication Date
EP0950044A1 true EP0950044A1 (fr) 1999-10-20
EP0950044A4 EP0950044A4 (fr) 2003-03-26

Family

ID=11069615

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97954134A Withdrawn EP0950044A4 (fr) 1996-12-24 1997-12-24 Preparation de gabapentine

Country Status (7)

Country Link
EP (1) EP0950044A4 (fr)
AU (1) AU5799098A (fr)
CA (1) CA2275912A1 (fr)
DE (1) DE97954134T1 (fr)
ES (1) ES2204362T1 (fr)
IL (1) IL119890A (fr)
WO (1) WO1998028255A1 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2137137B1 (es) * 1998-05-25 2000-08-16 Medichem Sa Nuevo polimorfo de gabapentina no hidratada, su procedimiento de obtencion y su utilizacion para la obtencion de gabapentina de calidad farmaceutica.
IT1311984B1 (it) * 1999-03-26 2002-03-22 Bioindustria Lab Italiano Medi Procedimento per la preparzione di gabapentin.
CA2370030C (fr) 1999-04-09 2007-08-14 Euro-Celtique S.A. Composition de blocage du canal sodique et leur utilisation
ES2164527B1 (es) * 1999-04-26 2003-04-01 Medichen S A Procedimiento de obtencion de gabapentina de calidad farmaceutica.
US6294198B1 (en) 1999-08-24 2001-09-25 Purepac Pharmaceutical Co. Pharmaceutical tablet formulation containing gabapentin with improved physical and chemical characteristics and method of making the same
DE60025143T2 (de) * 1999-11-22 2006-07-06 Akzo Nobel N.V. Verfahren und Zusammensetzung zur Herstellung von Wasserstoffperoxid
WO2001097612A1 (fr) * 2000-06-16 2001-12-27 Teva Pharmaceutical Industries Ltd. Gabapentine stable contenant plus de 20 ppm d'ions chlore
EP1430893A1 (fr) * 2000-06-16 2004-06-23 Teva Pharmaceutical Industries Ltd. Gabapentin stable contenant plus de 20 ppm d'ions chlore
SK302003A3 (en) * 2000-06-16 2003-07-01 Teva Pharma Stable gabapentin having pH within a controlled range
EP1384473A1 (fr) * 2000-06-16 2004-01-28 Teva Pharmaceutical Industries Ltd. Gabapentin stable contenant plus de 20 ppm d'ions chlore
US7056951B2 (en) 2000-09-26 2006-06-06 Mutual Pharmaceutical Co., Inc. Stable solid dosage forms of amino acids and processes for producing same
IT1319674B1 (it) * 2000-12-01 2003-10-23 Erregierre Spa Processo per la preparazione dell'acido1-(aminometil)cicloesanacetico.
JP4350508B2 (ja) 2001-09-03 2009-10-21 ニユーロン・フアーマシユーテイカルズ・エツセ・ピー・アー ガバペンチンまたはその類似体とα−アミノアミドとを含む薬剤組成物およびその鎮痛用途
US6800782B2 (en) 2001-10-09 2004-10-05 Warner-Lambert Co. Anhydrous crystalline forms of gabapentin
US20030158254A1 (en) * 2002-01-24 2003-08-21 Xenoport, Inc. Engineering absorption of therapeutic compounds via colonic transporters
WO2004046084A1 (fr) 2002-11-18 2004-06-03 Nicholas Piramal India Limited Procede ameliore pour la preparation de gabapentine
EP1603863B1 (fr) * 2002-11-20 2010-01-13 Hikal Ltd. Procede de preparation d'acides amino-methyl-cycloalcane acetiques
WO2004093779A2 (fr) * 2003-04-21 2004-11-04 Matrix Laboratories Ltd Procede relatif a l'elaboration de gabapentine de forme-ii
EP1615875A2 (fr) * 2003-04-21 2006-01-18 Matrix Laboratories Limited Processus de preparation de gabapentine forme ii
WO2004106281A1 (fr) * 2003-05-30 2004-12-09 Ranbaxy Laboratories Limited Gabapentine cristallin
WO2004110342A2 (fr) * 2003-06-12 2004-12-23 Matrix Laboratories Ltd Nouveau polymorphe de gabapentine et sa conversion en gabapentine de forme ii
WO2004110981A1 (fr) * 2003-06-12 2004-12-23 Matrix Laboratories Ltd Procede permettant la preparation de gabapentine de forme ii
US7169812B2 (en) 2003-07-01 2007-01-30 Medtronic, Inc. Process for producing injectable gabapentin compositions
ITMI20040579A1 (it) 2004-03-25 2004-06-25 Zambon Spa Processo di preparazione di gabapentina
GB0415076D0 (en) * 2004-07-05 2004-08-04 Sandoz Ind Products S A Process for the preparation of gabapentin
GB0416228D0 (en) 2004-07-20 2004-08-25 Sandoz Ind Products S A Process for the preparation of gabapentin
EP2007710A1 (fr) * 2007-02-28 2008-12-31 Teva Pharmaceutical Industries Ltd. Preparation de gabapentine par extraction liquide-liquide
WO2009015685A1 (fr) 2007-07-27 2009-02-05 Medichem, S.A. Procédé de préparation de la forme polymorphe ii de la gabapentine
CN102363598B (zh) * 2011-11-25 2014-02-12 浙江精进药业有限公司 高纯度加巴喷丁的制备方法
ITMI20131757A1 (it) 2013-10-22 2015-04-23 Zach System Spa Processo di preparazione di gabapentina

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US4960931A (en) * 1988-05-02 1990-10-02 Warner-Lambert Company Gabapentin mohohydrate and a process for producing the same
DE3928184A1 (de) * 1989-08-25 1991-02-28 Goedecke Ag Verfahren zur herstellung von cyclischen aminosaeurederivaten sowie zwischenprodukte

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *
See also references of WO9828255A1 *

Also Published As

Publication number Publication date
IL119890A (en) 2002-03-10
WO1998028255A1 (fr) 1998-07-02
CA2275912A1 (fr) 1998-07-02
AU5799098A (en) 1998-07-17
DE97954134T1 (de) 2004-04-15
IL119890A0 (en) 1997-03-18
ES2204362T1 (es) 2004-05-01
EP0950044A4 (fr) 2003-03-26

Similar Documents

Publication Publication Date Title
US6255526B1 (en) Preparation of gabapentin
WO1998028255A1 (fr) Preparation de gabapentine
EP2327708A2 (fr) Procédé de purification d'adefovir dipivoxil
JP2007536209A (ja) １−ベンジル−４−［（５，６−ジメトキシ−１−インダノン）−２−イル］メチルピペリジンシュウ酸塩（シュウ酸ドネペジル）およびその多形
JPS585904B2 (ja) グアニジン及びその塩類の製造方法
CN109836424B (zh) 一种环保型茶碱钠盐甲基化制备咖啡因的方法
RU2586117C2 (ru) Кристаллизация гидрохлорида эпирубицина
JP2988019B2 (ja) Ｎ−アルキルアミノエタンスルホン酸ナトリウムの製造方法
EP0611369A1 (fr) Procede de preparation (s) (+)-4,4'-(1-methyl-1,2-ethanediyl-bis-(2,6-piperazinedione)
WO2008096373A2 (fr) Procédé de synthèse de polymorphes de natéglinide extrêmement pure
KR101287425B1 (ko) 글리세릴 포스포릴 콜린 ii형 결정의 제조방법
KR101287422B1 (ko) 글리세릴 포스포릴 콜린의 i형 결정
JP3042122B2 (ja) Ｎ−シアノアセトアミジン誘導体の製造方法
JP3848714B2 (ja) エチレンジアミン−ｎ，ｎ’−ジコハク酸およびその第二鉄錯塩の製法
KR101287423B1 (ko) 글리세릴 포스포릴 콜린의 ii형 결정
CN109689620A (zh) 拆分巴氯芬盐的方法
JP2942380B2 (ja) メタクリルアミドの精製方法
JPH10316646A (ja) 高純度の結晶質ｏ−メチルイソ尿素酢酸塩の製造方法及び該方法で得られた結晶質ｏ−メチルイソ尿素酢酸塩
CN113087680A (zh) Dota晶型及其制备方法
JPH1180099A (ja) （１ｓ，２ｒ）−１−アミノ−２−インダノール−（ｒ，ｒ）−タートレート メタノール溶媒和物の調製方法
EP1853551A1 (fr) Procede et methodes de preparation de gabapentine et de produits intermediaires du gabapentine
JP2770512B2 (ja) アミノエチルスルホン酸アルカリ金属塩類の精製方法
CN117186163A (zh) 一种三氯蔗糖-6-乙酸酯提纯工艺
CN117164464A (zh) 一种曲恩汀水合物的晶型及其制备方法
JP2576598B2 (ja) 光学活性１−メチル−３−フェニルプロピルアミンの製法

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990721

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20030212

RIC1 Information provided on ipc code assigned before grant

Ipc: 7C 07C 229/28 B

Ipc: 7C 07C 227/40 A

17Q First examination report despatched

Effective date: 20030318

EL Fr: translation of claims filed
REG Reference to a national code

Ref country code: SE

Ref legal event code: TRCL

TCNL Nl: translation of patent claims filed
TCAT At: translation of patent claims filed
REG Reference to a national code

Ref country code: GR

Ref legal event code: PP

Ref document number: 20030300027

Country of ref document: GR

DET De: translation of patent claims
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1023333

Country of ref document: HK

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1027090

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070317